Page last updated: 2024-10-27

flutamide and Impotence

flutamide has been researched along with Impotence in 14 studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Research Excerpts

ExcerptRelevanceReference
" We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate."9.08Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. ( Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P, 1997)
" We evaluated a combination of finasteride and flutamide as potency-sparing androgen ablative therapy (AAT) for advanced adenocarcinoma of the prostate."5.08Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. ( Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P, 1997)
"Treatment of localized prostate cancer (PC) is controversial."2.80Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. ( Albertsson, P; Brandberg, Y; Damber, JE; Damm, O; Holmberg, E; Isacsson, U; Lennernäs, B; Ljung, G; Majumder, K; Nilsson, S, 2015)
"After disease progression, patients treated with bicalutamide were assigned to castration."2.69Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. ( Barichello, M; Battaglia, M; Boccardo, F; Carmignani, G; Comeri, G; Conti, G; Cruciani, G; Dammino, S; Delliponti, U; Ditonno, P; Ferraris, V; Lilliu, S; Montefiore, F; Portoghese, F; Rubagotti, A; Spano, G, 1999)
" Hepatic toxicity may limit the long-term use of both drugs."2.69Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. ( Collette, L; de Reijke, TM; Schröder, FH; Whelan, P, 2000)
"Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life."1.35Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. ( Dewilde, S; Kleinman, L; Lloyd, A; Penson, D, 2008)
") erections we assessed the dose-response effects of p,p-DDE in comparison to the known androgen receptor antagonist flutamide in acute (0."1.31Effects of an environmental anti-androgen on erectile function in an animal penile erection model. ( Adams, MA; Brien, SE; Heaton, JP; Racz, WJ, 2000)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19901 (7.14)18.7374
1990's6 (42.86)18.2507
2000's5 (35.71)29.6817
2010's2 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lennernäs, B1
Majumder, K1
Damber, JE1
Albertsson, P1
Holmberg, E1
Brandberg, Y1
Isacsson, U1
Ljung, G1
Damm, O1
Nilsson, S1
Jones, CU1
Hunt, D1
McGowan, DG1
Amin, MB1
Chetner, MP1
Bruner, DW1
Leibenhaut, MH1
Husain, SM1
Rotman, M1
Souhami, L1
Sandler, HM1
Shipley, WU1
Lamb, DS1
Denham, JW1
Mameghan, H1
Joseph, D1
Turner, S1
Matthews, J1
Franklin, I1
Atkinson, C1
North, J1
Poulsen, M1
Kovacev, O1
Robertson, R1
Francis, L1
Christie, D1
Spry, NA1
Tai, KH1
Wynne, C1
Duchesne, G1
Lloyd, A1
Penson, D1
Dewilde, S1
Kleinman, L1
Fleshner, NE1
Trachtenberg, J1
Stevens, MJ1
Bell, DR1
Blome, SA1
Begbie, SD1
Brufsky, A1
Fontaine-Rothe, P1
Berlane, K1
Rieker, P1
Jiroutek, M1
Kaplan, I1
Kaufman, D1
Kantoff, P1
Boccardo, F1
Rubagotti, A1
Barichello, M1
Battaglia, M1
Carmignani, G1
Comeri, G1
Conti, G1
Cruciani, G1
Dammino, S1
Delliponti, U1
Ditonno, P1
Ferraris, V1
Lilliu, S1
Montefiore, F1
Portoghese, F1
Spano, G1
Schröder, FH1
Collette, L1
de Reijke, TM1
Whelan, P1
Brien, SE1
Heaton, JP1
Racz, WJ1
Adams, MA1
Iversen, P1
Melezinek, I1
Schmidt, A1
Pavone-Macaluso, M2
Serretta, V1
Daricello, G1
Pavone, C1
Cacciatore, M1
Romano, C1
Cavallo, N1
Rousseau, L1
Dupont, A1
Labrie, F1
Couture, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
ULTRA-HYPO Fractionated (UHF) Compared to Moderate-HYPO Fractionated (MHF) Prostate IGRT With HDR Brachytherapy BOOST : A Phase 1-2 Study.[NCT05786742]205 participants (Anticipated)Interventional2014-04-30Recruiting
A PHASE III TRIAL OF THE STUDY OF ENDOCRINE THERAPY USED AS A CYTOREDUCTIVE AND CYTOSTATIC AGENT PRIOR TO RADIATION THERAPY IN GOOD PROGNOSIS LOCALLY CONFINED ADENOCARCINOMA OF THE PROSTATE[NCT00002597]Phase 32,028 participants (Actual)Interventional1994-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Biochemical Failure Rate (10 Years)

The Phoenix definition of biochemical failure was used - an increase in the prostate-specific antigen (PSA) level of >2 ng per milliliter above the nadir. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years

Interventionpercentage of participants (Number)
Hormone Therapy + Radiation Therapy26.3
Radiation Therapy Alone41.1

Clinical Relapse Rate (10 Years)

Clinical relapse is defined as local progression or distant metastases. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years

Interventionpercentage of participants (Number)
Hormone Therapy + Radiation Therapy15.0
Radiation Therapy Alone21.7

Disease-free Survival Rate (10 Years)

Disease-free failure is defined as documentation of progression (local progression, distant failure, and biochemical failure) or death from any cause. Disease-free survival rates were estimated by the Kaplan-Meier method. (NCT00002597)
Timeframe: From registration to 10 years

Interventionpercentage of participants (Number)
Hormone Therapy + Radiation Therapy51.7
Radiation Therapy Alone39.5

Disease-specific Survival Rate (10 Years)

Disease-specific failure is defined as death certified as due to prostate cancer (by central review), death due to complications of treatment (irrespective of malignancy status), death from unknown causes with active malignancy, or death from unknown causes with previously documented relapse (either clinical or biochemical). Survival rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years

Interventionpercentage of participants (Number)
Hormone Therapy + Radiation Therapy95.7
Radiation Therapy Alone92.6

Distant Failure Rate (10 Years)

Failure is defined as documented metastatic disease. Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years

Interventionpercentage of participants (Number)
Hormone Therapy + Radiation Therapy5.5
Radiation Therapy Alone8.0

Local Progression Rate (10 Years)

Local progression defined as documented local progression as determined by clinical exam . Failure rates were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years

Interventionpercentage of participants (Number)
Hormone Therapy + Radiation Therapy10.9
Radiation Therapy Alone16.1

Overall Survival Rate (10-year)

Overall survival (OS) was calculated from randomization to the date of death from any cause and overall survival rates were estimated by the Kaplan-Meier method. (NCT00002597)
Timeframe: From date of randomization to 10 years

Interventionpercentage of patients (Number)
Hormone Therapy + Radiation Therapy61.9
Radiation Therapy Alone56.8

Positive Re-biopsy Rate at Two Years

The rate of prostate rebiopsy at two years is defined as the proportion of patients whose results are positive among all eligible patients who had a repeat biopsy at two years. The rate was estimated separately in each arm. (NCT00002597)
Timeframe: From registration to two years

Interventionpercentage of participants (Number)
Hormone Therapy + Radiation Therapy20.2
Radiation Therapy Alone38.9

Second Biochemical Relapse Rate (10 Years)

Second biochemical relapse is as defined as follows (after initiation of salvage hormone therapy): A rise in PSA on at least two consecutive cases above the nadir (after initiation of salvage hormone therapy), with the rises in PSA exceeding 1 ng/ml above the nadir; or failure to reach 4 ng/L or less at 18 months. The rates of second biochemical relapse were estimated by means of cumulative incidence functions. (NCT00002597)
Timeframe: From registration to 10 years

Interventionpercentage of participants (Number)
Hormone Therapy + Radiation Therapy2.7
Radiation Therapy Alone6.1

Reviews

2 reviews available for flutamide and Impotence

ArticleYear
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
    BJU international, 2001, Volume: 87, Issue:1

    Topics: Androgen Antagonists; Anilides; Erectile Dysfunction; Flutamide; Humans; Imidazoles; Imidazolidines;

2001
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Progress in clinical and biological research, 1990, Volume: 350

    Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E

1990

Trials

8 trials available for flutamide and Impotence

ArticleYear
Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes.
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cost of Illness; Emotions; Erec

2015
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    The New England journal of medicine, 2011, Jul-14, Volume: 365, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi

2011
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    The New England journal of medicine, 2011, Jul-14, Volume: 365, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi

2011
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    The New England journal of medicine, 2011, Jul-14, Volume: 365, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi

2011
Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    The New England journal of medicine, 2011, Jul-14, Volume: 365, Issue:2

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combi

2011
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2003, Volume: 68, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy,

2003
Prolonged hypogonadism after pulsed gonadotropin-releasing hormone agonist for prostate cancer.
    Lancet (London, England), 1994, Jul-23, Volume: 344, Issue:8917

    Topics: Combined Modality Therapy; Erectile Dysfunction; Flutamide; Follicle Stimulating Hormone; Goserelin;

1994
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
    Urology, 1997, Volume: 49, Issue:6

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Fl

1997
Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; An

1999
Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.
    British journal of cancer, 2000, Volume: 82, Issue:2

    Topics: Aged; Androgen Antagonists; Cyproterone; Erectile Dysfunction; Flutamide; Humans; Male; Middle Aged;

2000
Is there a role for pure antiandrogens in the treatment of advanced prostatic cancer?
    Progress in clinical and biological research, 1990, Volume: 350

    Topics: Aged; Aged, 80 and over; Anilides; Combined Modality Therapy; Diethylstilbestrol; Drug Evaluation; E

1990

Other Studies

5 other studies available for flutamide and Impotence

ArticleYear
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
    Prostate cancer and prostatic diseases, 2008, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Choice Behavi

2008
Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results.
    European urology, 1993, Volume: 24 Suppl 2

    Topics: Aged; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Flutamide; Humans; Luteinizing H

1993
Effects of an environmental anti-androgen on erectile function in an animal penile erection model.
    The Journal of urology, 2000, Volume: 163, Issue:4

    Topics: Androgen Antagonists; Animals; Castration; Dichlorodiphenyl Dichloroethylene; Dose-Response Relation

2000
Are organ preservation and maintenance of sexual function compatible with optimal management of prostate cancer? Part 2--Advanced cancer.
    Progress in clinical and biological research, 1991, Volume: 370

    Topics: Androgen Antagonists; Combined Modality Therapy; Erectile Dysfunction; Flutamide; Humans; Imidazoles

1991
Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration.
    Archives of sexual behavior, 1988, Volume: 17, Issue:1

    Topics: Aged; Anilides; Combined Modality Therapy; Drive; Erectile Dysfunction; Flutamide; Humans; Male; Mid

1988